Skip to main content

Search

Reset all filters
708 Result(s)
Sort by

Our forward-looking approach drives breakthroughs

Our forward-looking approach drives breakthroughs

Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
Our Culture of Caring: Volunteering

Our Culture of Caring: Volunteering

At BI we are committed to improving the health and well-being of people & animals. We encourage & support employee volunteer activities.
Leadership insights about our focus on patient centricity

Leadership insights about our focus on patient centricity

Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement
Corporate Compliance Program

Corporate Compliance Program

Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations
OUR FOCUS

OUR FOCUS

Our FOCUS is the cultural framework for our company. It describes who we are and what we strive for, why we exist, how we work and what we want to achieve.
Boehringer Ingelheim Office Hours Video 2023

Boehringer Ingelheim Office Hours Video 2023

Video providing an overview of Boehringer Ingelheim’s Office Hours program and how its mentoring and access to expertise can help early-stage companies advance their science.
Boehringer Ingelheim hosts Governor Lamont press conference at our Apple Blossom learning center to support more on-site childcare options in Connecticut

Boehringer Ingelheim hosts Governor Lamont press conference at our Apple Blossom learning center to support more on-site childcare options in Connecticut

Read about Connecticut Governor Ned Lamont and his administration’s visit to our U.S. headquarters in Ridgefield to tour our Apple Blossom Children’s Learning Center, to express the need for more childcare options for local communities and businesses.
Innovating for our business

Innovating for our business

We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
The Core of our Leitbild

The Core of our Leitbild

Click here to find out more about Boehringer Ingelheim's core values and mission statement, highlighting our key business focuses.